Ascendis Pharma A/S (Ascendis Pharma A/S) Short-Term Capital Lease Obligation

: $15.5 Mil (As of Dec. 2023)

View and export this data going back to 2015. Start your Free Trial

Ascendis Pharma A/S's Short-Term Capital Lease Obligation for the quarter that ended in Dec. 2023 was $15.5 Mil.

Ascendis Pharma A/S's quarterly Short-Term Capital Lease Obligation increased from Jun. 2023 ($0.0 Mil) to Sep. 2023 ($15.4 Mil) and increased from Sep. 2023 ($15.4 Mil) to Dec. 2023 ($15.5 Mil).

Ascendis Pharma A/S's annual Short-Term Capital Lease Obligation increased from Dec. 2021 ($7.9 Mil) to Dec. 2022 ($14.6 Mil) and increased from Dec. 2022 ($14.6 Mil) to Dec. 2023 ($15.5 Mil).

Ascendis Pharma A/S Short-Term Capital Lease Obligation Historical Data

The historical data trend for Ascendis Pharma A/S's Short-Term Capital Lease Obligation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ascendis Pharma A/S Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Capital Lease Obligation

6.55

8.34

7.90

14.61

15.46

Ascendis Pharma A/S Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Short-Term Capital Lease Obligation																14.61	-	-	15.40	15.46

Ascendis Pharma A/S Short-Term Capital Lease Obligation Explanation

Short-Term Capital Lease Obligation represents the total amount of Long-Term Capital Lease Obligation that must be paid within the next accounting period. Capital lease obligations are contractual obligations that arise from obtaining the use of property or equipment via a capital lease contract.

Ascendis Pharma A/S Short-Term Capital Lease Obligation Related Terms

Thank you for viewing the detailed overview of Ascendis Pharma A/S's Short-Term Capital Lease Obligation provided by GuruFocus.com. Please click on the following links to see related term pages.

Ascendis Pharma A/S (Ascendis Pharma A/S) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ascendis Pharma A/S (NAS:ASND) » Definitions » Short-Term Capital Lease Obligation

Comparable Companies

Traded in Other Exchanges

ASND:Mexico A71:Germany A1SN34:Brazil

Address

Tuborg Boulevard 12, Hellerup, DNK, DK-2900

Website

http://www.ascendispharma.com

Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates in North America, China, and Europe and derives the majority of its revenue from North America.